Medifast Q2 Earnings Call Highlights

Q2 performance weakened: Revenue fell 27.6% year over year to $76.4 million, and Medifast posted a $3.1 million net loss as its active earning coach base declined nearly 49%. However, revenue per active coach increased 41% to $6,529, marking a third consecutive quarter of productivity improvement. Trilivy anchors the strategic reset: Medifast is shifting from traditional weight loss toward metabolic health through its new Trilivy brand, upcoming Reset Fuelings, the Metabolic Health Institute and an enhanced coach compensation plan. Management is targeting a Q4 return to profitability: The Catalyst cost program is expected to generate millions in savings through facility rationalization, AI efficiencies and other streamlining. Medifast ended June with $169.8 million in cash and investments, no debt, and reiterated its fourth-quarter 2026 profitability goal.

Medifast NYSE: MED reported second-quarter 2026 revenue of $76.4 million, down 27.6% from a year earlier, as its active earning coach base continued to decline amid the rapid adoption of GLP-1 medications across the traditional weight-loss category. The company posted a net loss of $3.1 million, or $0.28 per diluted share, compared with net income of $2.5 million, or $0.22 per share, in the prior-year quarter. Management said revenue met its guidance range and earnings per share exceeded guidance, supported by a third consecutive quarter of improvement in coach productivity. Medifast ended the quarter with about 11,700 active earning coaches, a 48.7% decrease from the second quarter of 2025. However, average revenue per active earning coach rose 41% year over year to $6,529 and increased 20% sequentially, reaching its highest level since the second quarter of 2022.

“We now have a clear trend of increasing coach productivity both year-over-year and sequentially,” Chief Financial Officer Jim Maloney said. The company views higher revenue per coach as an early indicator that could eventually lead to coach growth and revenue growth.

Trilivy Launch Anchors Metabolic Health Strategy Chief Executive Officer Nicholas Johnson, speaking on his first earnings call in the role, said the company is pursuing a broader transition from weight loss toward metabolic health. Medifast launched its Trilivy consumer brand as the successor to OPTAVIA and described it as the first step in its “3.0 strategy,” a 10-year roadmap focused on expanding its offerings, geographic reach and demographic footprint. Johnson said Trilivy is designed around three phases—reset, refine and renew—and positions the company’s coach-led nutrition programs as a comprehensive metabolic health system. The company also launched the Medifast Metabolic Health Institute in July, which will organize research, product development, scientific communications and education. The company plans to introduce new Reset Fuelings later in August. The products include Medifast’s MetaVantage Technology Reset Formula, which the company said is intended to support normal fat metabolism, healthy insulin function and reduced waist circumference. Johnson said a spring pilot involving certain employees, coaches and clients generated “overwhelmingly positive” feedback. Medifast also launched an enhanced coach compensation plan on Aug. 1, emphasizing the development of executive directors. Johnson said executive directors are the company’s highest-producing coaches and represent “the single greatest driver of sustainable growth” for the business. The percentage of active earning coaches at the executive director rank or above remained above the company’s 10...